Barely Significant
← all excerpts

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.

Cancers (Basel) · 2022 · PMC9323840 · PMID 35884533

Europe PMCDOI
1
hedged sentence
0.3000
closest p · 6.0× alpha
0.3000
boldest claim

The sentences

showed a trendp = 0.3not close (p > 0.1)
The addition of anti-VEGF therapy showed a trend toward potential benefit compared with chemotherapy only (mPFS, 6.1 vs. 4.8 months, p = 0.3).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.